CA3038504A1 - Modular tetrameric bispecific antibody platform - Google Patents

Modular tetrameric bispecific antibody platform Download PDF

Info

Publication number
CA3038504A1
CA3038504A1 CA3038504A CA3038504A CA3038504A1 CA 3038504 A1 CA3038504 A1 CA 3038504A1 CA 3038504 A CA3038504 A CA 3038504A CA 3038504 A CA3038504 A CA 3038504A CA 3038504 A1 CA3038504 A1 CA 3038504A1
Authority
CA
Canada
Prior art keywords
amino acid
seq
acid sequence
cdrs
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3038504A
Other languages
English (en)
French (fr)
Inventor
Wayne A. Marasco
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of CA3038504A1 publication Critical patent/CA3038504A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CA3038504A 2016-10-14 2017-10-16 Modular tetrameric bispecific antibody platform Pending CA3038504A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662408271P 2016-10-14 2016-10-14
US62/408,271 2016-10-14
PCT/US2017/056814 WO2018071913A2 (en) 2016-10-14 2017-10-16 Modular tetrameric bispecific antibody platform

Publications (1)

Publication Number Publication Date
CA3038504A1 true CA3038504A1 (en) 2018-04-19

Family

ID=60327374

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3038504A Pending CA3038504A1 (en) 2016-10-14 2017-10-16 Modular tetrameric bispecific antibody platform

Country Status (7)

Country Link
US (2) US20200017588A1 (cg-RX-API-DMAC10.html)
EP (1) EP3526257A2 (cg-RX-API-DMAC10.html)
JP (3) JP7269167B2 (cg-RX-API-DMAC10.html)
CN (2) CN110214152B (cg-RX-API-DMAC10.html)
AU (2) AU2017341936B2 (cg-RX-API-DMAC10.html)
CA (1) CA3038504A1 (cg-RX-API-DMAC10.html)
WO (1) WO2018071913A2 (cg-RX-API-DMAC10.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3031194A1 (en) * 2016-07-22 2018-01-25 Dana-Farber Cancer Institute, Inc. Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof
EP3526257A2 (en) * 2016-10-14 2019-08-21 Dana-Farber Cancer Institute, Inc. Modular tetravalent bispecific antibody platform
WO2018145075A1 (en) * 2017-02-06 2018-08-09 Dana-Farber Cancer Institute, Inc. Compositions and methods for augmenting antibody mediated receptor signaling
EP3880247A4 (en) * 2018-11-13 2022-10-26 JN Biosciences, LLC Bispecific antibodies for activation of immune cells
JP2022510218A (ja) * 2018-11-30 2022-01-26 メモリアル スローン ケタリング キャンサー センター ヘテロ二量体四価特異性抗体およびこれらの使用
CA3159308A1 (en) * 2019-12-02 2021-06-10 Wayne A. Marasco Antibodies against pd-l1 and methods of use thereof
CN113563473A (zh) * 2020-04-29 2021-10-29 三生国健药业(上海)股份有限公司 四价双特异性抗体、其制备方法和用途
WO2021226984A1 (zh) * 2020-05-15 2021-11-18 三生国健药业(上海)股份有限公司 一种抗pd-1和pd-l1的四价双特异性抗体
AU2022227686A1 (en) 2021-02-25 2023-07-27 Lyell Immunopharma, Inc. Ror1 targeting chimeric antigen receptor
WO2023034288A1 (en) 2021-08-31 2023-03-09 Dana-Farber Cancer Institute, Inc. Compositions and methods for treatment of autoimmune disorders and cancer
WO2023097024A1 (en) 2021-11-24 2023-06-01 Dana-Farber Cancer Institute, Inc. Antibodies against ctla-4 and methods of use thereof
AU2023232045A1 (en) 2022-03-09 2024-09-26 Dana-Farber Cancer Institute, Inc. Genetically engineered b cells and methods of use thereof
CA3263665A1 (en) 2022-08-15 2024-02-22 Dana-Farber Cancer Institute, Inc. Anti-CLDN4 antibodies and their methods of use
WO2024039672A2 (en) 2022-08-15 2024-02-22 Dana-Farber Cancer Institute, Inc. Antibodies against msln and methods of use thereof
CN121399164A (zh) * 2023-06-20 2026-01-23 戴纳立制药公司 双重转运体及使用方法
WO2026117666A1 (en) * 2024-11-26 2026-06-04 Dana-Farber Cancer Institute, Inc. Bispecific antibodies for treating cancer
WO2026117664A1 (en) * 2024-11-26 2026-06-04 Dana-Farber Cancer Institute, Inc. Engineered cells and uses thereof for treating cancer

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
DE4118120A1 (de) * 1991-06-03 1992-12-10 Behringwerke Ag Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
WO2003002144A1 (en) * 2001-06-26 2003-01-09 Imclone Systems Incorporated Bispecific antibodies that bind to vegf receptors
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
CN1914226B (zh) 2003-11-25 2012-02-01 达纳-法伯癌症研究院有限公司 SARS-CoV抗体及其使用方法
EP1695093A1 (en) * 2003-12-05 2006-08-30 multimmune GmbH Compositions and methods for the treatment and diagnosis of neoplastic and infectious diseases
WO2006074399A2 (en) * 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
US8329178B2 (en) 2005-02-18 2012-12-11 Dana-Farber Cancer Institute, Inc. Antibodies against CXCR4 and methods of use thereof
EP1979379B1 (en) 2005-12-02 2013-09-18 Dana-Farber Cancer Institute Carbonic anhydrase ix (g250) antibodies and methods of use thereof
EP3524619A1 (en) 2007-12-06 2019-08-14 Dana-Farber Cancer Institute, Inc. Antibodies against influenza virus and methods of use thereof
WO2009086514A1 (en) 2007-12-28 2009-07-09 Dana-Farber Cancer Institute, Inc. Humanized monoclonal antibodies and methods of use
JP2011524966A (ja) * 2008-02-22 2011-09-08 ダウ グローバル テクノロジーズ エルエルシー 熱エネルギー貯蔵材料
US20130089554A1 (en) 2009-12-29 2013-04-11 Emergent Product Development Seattle, Llc RON Binding Constructs and Methods of Use Thereof
EP3957653A1 (en) 2010-06-02 2022-02-23 Dana Farber Cancer Institute, Inc. Humanized monoclonal antibodies and methods of use
EP2543680A1 (en) * 2011-07-07 2013-01-09 Centre National de la Recherche Scientifique Multispecific mutated antibody Fab fragments
CN103906533A (zh) * 2011-11-07 2014-07-02 米迪缪尼有限公司 多特异性和多价结合蛋白及其用途
CN104203981A (zh) * 2011-12-19 2014-12-10 合成免疫股份有限公司 双特异性抗体分子
EP2794662A1 (en) * 2011-12-22 2014-10-29 F.Hoffmann-La Roche Ag Full length antibody display system for eukaryotic cells and its use
US8961971B2 (en) 2011-12-22 2015-02-24 Development Center For Biotechnology Bispecific T-cell activator antibody
EP2814846B1 (en) * 2012-02-13 2020-01-08 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
AU2013256010B2 (en) 2012-05-04 2018-01-04 Dana-Farber Cancer Institute, Inc. Affinity matured anti-CCR4 humanized monoclonal antibodies and methods of use
EP2850106B1 (en) * 2012-05-18 2022-03-23 Aptevo Research and Development LLC Bispecific scfv immunofusion (bif) binding to cd123 and cd3
BR112015007672A2 (pt) 2012-10-04 2017-08-08 Dana Farber Cancer Inst Inc anticorpos anti-pd-l1 monoclonais humanos e métodos de uso
EP2920210B1 (en) * 2012-11-19 2017-08-30 Baliopharm AG Recombinant bispecific antibody binding to cd20 and cd95
CN105530959B (zh) 2013-03-15 2021-09-17 纪念斯隆-凯特琳癌症中心 多聚化技术
EP4292657A3 (en) 2013-03-15 2024-03-20 Dana Farber Cancer Institute, Inc. Flavivirus neutralizing antibodies and methods of use thereof
SG11201509566RA (en) 2013-05-20 2015-12-30 Genentech Inc Anti-transferrin receptor antibodies and methods of use
AR097306A1 (es) * 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
KR20160122127A (ko) * 2013-12-23 2016-10-21 자임워크스 인코포레이티드 C-말단의 경쇄 폴리펩타이드 연장부를 포함하는 항체 및 이의 컨쥬게이트 및 이들의 사용방법
EP3119804A2 (en) 2014-03-19 2017-01-25 Dana-Farber Cancer Institute, Inc. Immunogenetic restriction on elicitation of antibodies
WO2015164865A1 (en) 2014-04-25 2015-10-29 Dana-Farber Cancer Institute, Inc. Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof
PL3151921T3 (pl) * 2014-06-06 2020-02-28 Bristol-Myers Squibb Company Przeciwciała przeciwko receptorowi indukowanego glukokortykoidami czynnika martwicy nowotworu (gitr) i ich zastosowania
WO2015197582A1 (en) 2014-06-27 2015-12-30 Innate Pharma Monomeric multispecific antigen binding proteins
RU2017115315A (ru) 2014-10-03 2018-11-08 Дана-Фарбер Кэнсер Инститьют, Инк. Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения
CA2962949C (en) 2014-10-06 2024-03-05 Dana-Farber Cancer Institute, Inc. Humanized cc chemokine receptor 4 (ccr4) antibodies and methods of use thereof
US11135282B2 (en) 2015-04-08 2021-10-05 Dana-Farber Cancer Institute, Inc. Humanized influenza monoclonal antibodies and methods of use thereof
EP3526257A2 (en) * 2016-10-14 2019-08-21 Dana-Farber Cancer Institute, Inc. Modular tetravalent bispecific antibody platform
JP7649239B2 (ja) * 2018-11-30 2025-03-19 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド キメラ抗原受容体ファクトリおよびその使用方法

Also Published As

Publication number Publication date
JP2019533675A (ja) 2019-11-21
CN110214152A (zh) 2019-09-06
EP3526257A2 (en) 2019-08-21
AU2025200665A1 (en) 2025-04-10
US20260193357A1 (en) 2026-07-09
JP7269167B2 (ja) 2023-05-08
CN120795163A (zh) 2025-10-17
WO2018071913A2 (en) 2018-04-19
US20200017588A1 (en) 2020-01-16
JP2023093642A (ja) 2023-07-04
WO2018071913A3 (en) 2018-05-24
AU2017341936A1 (en) 2019-04-04
CN110214152B (zh) 2025-06-13
JP2025142045A (ja) 2025-09-29
JP7796079B2 (ja) 2026-01-08
AU2017341936B2 (en) 2024-10-31

Similar Documents

Publication Publication Date Title
US20200017588A1 (en) Modular tetravalent bispecific antibody platform
JP7345578B2 (ja) 新規抗pd-l1抗体
AU2020286284B2 (en) Novel anti-CD39 antibodies
JP6175590B1 (ja) 癌の治療に用いるための細胞傷害誘導治療剤
EP3055330B1 (en) Molecule
BRPI0611194B1 (pt) Moléculas de ligação anti-cd16
KR20220147631A (ko) 면역 반응을 조절하기 위한 물질 및 방법
AU2018360800A1 (en) Chimeric antigen receptors specific for B-cell maturation antigen (BCMA)
AU2018241535A1 (en) Tumor antigen presentation inducer constructs and uses thereof
JP2020503015A (ja) 抗cd19のヒト化抗体及びcd19を標的とする免疫エフェクター細胞
CN112041335A (zh) 用于细胞免疫治疗的组合物和方法
TW202216745A (zh) 包含經修飾il-2多肽之多肽及其用途
CN113164780A (zh) 抗lap抗体变体及其用途
CN114127112A (zh) 与t细胞结合的多功能分子及其治疗自身免疫性病症的用途
WO2022006451A2 (en) Compositions and methods for tcr reprogramming using fusion proteins and pd-1 antibodies
US20230416394A1 (en) Novel conjugate molecules targeting cd39 and tgfbeta
TW202313699A (zh) 新型抗sirpa抗體
KR20230156727A (ko) 항-vsig4 항체 또는 이의 항원 결합 단편 및 용도
JP2026513651A (ja) Adgre2キメラ受容体nk細胞組成物及び使用方法
KR20210143096A (ko) Cd22에 특이적인 항체 및 이의 용도
JP2021529539A5 (cg-RX-API-DMAC10.html)
KR20230146032A (ko) Tgf-b 신호전달을 조절하기 위한 세포 치료 조성물 및 방법
TW202435913A (zh) 針對血癌之抗體
WO2023133424A2 (en) Compositions and methods for tcr reprogramming using fusion proteins and anti-pd-1 fusion peptides
HK40085531A (en) Materials and methods for modulating an immune response

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220929

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241011

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241011

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250612

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20251010

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251010

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251010

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20251208

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20251208

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251208